Emerging cellular and molecular targets in fibrosis: Implications for scleroderma pathogenesis and targeted therapy

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 607-614

  Castelino, Flavia V ^a   Varga, John ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Extracellular matrix; Fibrosis; Myofibroblasts; Senescence; Stiffness

Indexed keywords

BETA CATENIN; CHEMOKINE; EPHRIN; FASUDIL; FOCAL ADHESION KINASE; INTEGRIN; LYSOPHOSPHATIDIC ACID; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN LYSINE 6 OXIDASE; RHO KINASE; SIMTUZUMAB; SPHINGOSINE 1 PHOSPHATE; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

AUTOPHAGY; CELL AGING; CELL FATE; CROSS LINKING; EFFECTOR CELL; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FIBROSIS; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIVER FIBROSIS; MESENCHYME CELL; MOLECULARLY TARGETED THERAPY; MYOFIBROBLAST; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; REVIEW; SCLERODERMA; STEM CELL; SYSTEMIC SCLEROSIS; ANIMAL; FIBROBLAST; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; FIBROBLASTS; FIBROSIS; HUMANS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84927722050     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000110     Document Type: Review

References (51)

1. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med 2014; 2:416-428.
2. Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis-a lethal component of systemic sclerosis. Nat Rev Rheumatol 2014; 10:390-402.
3. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8:42-54.
4. O'Reilly S. Innate immunity in systemic sclerosis pathogenesis. Clin Sci (Lond) 2014; 126:329-337.
5. Sugiura H, Ichikawa T, Koarai A, et al. Activation of Toll-like receptor 3 augments myofibroblast differentiation. Am J Respir Cell Mol Biol 2009; 40:654-662.
6. Farina GA, York MR, Di Marzio M, et al. Poly(I:C) drives type I IFN-and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 2010; 130:2583-2593.
7. Bhattacharyya S, Kelley K, Melichian DS, et al. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013; 182:192-205.
8. Bhattacharyya S, Tamaki Z, Wang W, et al. Fibronectin EDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 2014; 6:232ra250.
9. Rajkumar VS, Howell K, Csiszar K, et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005; 7:R1113-R1123.
10. Cipriani P, Marrelli A, Benedetto PD, et al. Scleroderma mesenchymal stem cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis 2013; 16:595-607.
11. Sarkar A, Hochedlinger K. The Sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell 2013; 12:15-30.
12. Liu S, Herault Y, Pavlovic G, Leask A. Skin progenitor cells contribute to bleomycin-induced skin fibrosis. Arthritis Rheumatol 2014; 66:707-713.
13. Wei J, Fang F, Lam AP, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012; 64:2734-2745.
14. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54:1961-1973.
15. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011; 63:1707-1717.
16. Shea BS, Tager AM. Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis. Proc Am Thorac Soc 2012; 9:102-110.
17. Castelino FV, Seiders J, Bain G, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011; 63:1405-1415.
18. Tokumura A, Carbone LD, Yoshioka Y, et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009; 6:168-176.
19. Ingegnoli F, Boracchi P, Gualtierotti R, et al. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatology (Oxford) 2010; 49:797-805.
20. Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48:98-103.
21. Kowal-Bielecka O, Kowal K, Lewszuk A, et al. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005; 64:484-486.
22. Van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370:433-443.
23. Liakouli V, Cipriani P, Marrelli A, et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011; 10:590-594.
24. Bandinelli F, Del Rosso A, Gabrielli A, et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 2012; 30:S44-S49.
25. Luzina IG, Atamas SP, Wise R, et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003; 48:2262-2274.
26. Avouac J, Clemessy M, Distler JH, et al. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. Rheumatology (Oxford) 2011; 50:1494-1504.
27. Hatziapostolou M, Polytarchou C. Eph/ephrin system: in the quest of novel antiangiogenic therapies. Br J Pharmacol 2014. [Epub ahead of print]
28. Reich A, Meurer M, Eckes B, et al. Surface morphology and mechanical properties of fibroblasts from scleroderma patients. J Cell Mol Med 2009; 13:1644-1652.
29. Tse JR, Engler AJ. Stiffness gradients mimicking in vivo tissue variation regulate mesenchymal stem cell fate. PLoS One 2011; 6:e15978.
30. Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014; 124:1622-1635.
31. Maeda T, Sakabe T, Sunaga A, et al. Conversion of mechanical force into TGF-beta-mediated biochemical signals. Curr Biol 2011; 21:933-941.
32. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007; 179:1311-1323.
33. Liu S, Kapoor M, Denton CP, et al. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009; 60:2817-2821.
34. Vedrenne N, Coulomb B, Danigo A, et al. The complex dialogue between (myo)fibroblasts and the extracellular matrix during skin repair processes and ageing. Pathol Biol (Paris) 2012; 60:20-27.
35. Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2014; 503:126-130.
36. Liu S, Xu SW, Blumbach K, et al. Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J Cell Sci 2011; 123:3674-3682.
37. Shi-wen X, Thompson K, Khan K, et al. Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 2012; 51:2146-2154.
38. Akhmetshina A, Dees C, Pileckyte M, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008; 58:2553-2564.
39. Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013; 123:1096-1108.
40. Hao J, Zhang Y, Wang Y, et al. Role of extracellular matrix and YAP/TAZ in cell fate determination. Cell Signal 2013; 26:186-191.
41. Lee MJ, Ran Byun M, Furutani-Seiki M, et al. YAP and TAZ regulate skin wound healing. J Invest Dermatol 2014; 134:518-525.
42. Imajo M, Miyatake K, Iimura A, et al. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. EMBO J 2012; 31:1109-1122.
43. Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474:179-183.
44. Shweke N, Boulos N, Jouanneau C, et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 2008; 173:631-642.
45. Olsen KC, Epa AP, Kulkarni AA, et al. Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules. Am J Respir Cell Mol Biol 2014; 50:737-747.
46. Rimar D, Rosner I, Nov Y, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol 2014; 66:726-730.
47. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2013; 43:1430-1438.
48. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16:1009-1017.
49. Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting nox4-nrf2 redox imbalance. Sci Transl Med 2014; 6:231ra47.
50. Hernandez-Gea V, Friedman SL. Autophagy fuels tissue fibrogenesis. Autophagy 2012; 8:849-850.
51. Dumit VI, Kuttner V, Kappler J, et al. Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol 2014; 134:2321-2330.